FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308769923> ?p ?o ?g. }

• W4308769923 endingPage "18" @default.
• W4308769923 startingPage "3" @default.
• W4308769923 abstract "To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field.An international task force was formed and solicited three systematic literature research activities on safety and efficacy of disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs). The new evidence was discussed in light of the last update from 2019. A predefined voting process was applied to each overarching principle and recommendation. Levels of evidence and strengths of recommendation were assigned to and participants finally voted on the level of agreement with each item.The task force agreed on 5 overarching principles and 11 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); GCs; biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab including biosimilars), abatacept, rituximab, tocilizumab, sarilumab and targeted synthetic (ts) DMARDs, namely the Janus kinase inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib. Guidance on monotherapy, combination therapy, treatment strategies (treat-to-target) and tapering in sustained clinical remission is provided. Safety aspects, including risk of major cardiovascular events (MACEs) and malignancies, costs and sequencing of b/tsDMARDs were all considered. Initially, MTX plus GCs is recommended and on insufficient response to this therapy within 3-6 months, treatment should be based on stratification according to risk factors; With poor prognostic factors (presence of autoantibodies, high disease activity, early erosions or failure of two csDMARDs), any bDMARD should be added to the csDMARD; after careful consideration of risks of MACEs, malignancies and/or thromboembolic events tsDMARDs may also be considered in this phase. If the first bDMARD (or tsDMARD) fails, any other bDMARD (from another or the same class) or tsDMARD (considering risks) is recommended. With sustained remission, DMARDs may be tapered but should not be stopped. Levels of evidence and levels of agreement were high for most recommendations.These updated EULAR recommendations provide consensus on RA management including safety, effectiveness and cost." @default.
• W4308769923 created "2022-11-15" @default.
• W4308769923 creator A5000282057 @default.
• W4308769923 creator A5000542169 @default.
• W4308769923 creator A5000779664 @default.
• W4308769923 creator A5000798254 @default.
• W4308769923 creator A5000926745 @default.
• W4308769923 creator A5004597907 @default.
• W4308769923 creator A5006070255 @default.
• W4308769923 creator A5006123817 @default.
• W4308769923 creator A5007351753 @default.
• W4308769923 creator A5009471725 @default.
• W4308769923 creator A5011826741 @default.
• W4308769923 creator A5013051978 @default.
• W4308769923 creator A5013851404 @default.
• W4308769923 creator A5016937274 @default.
• W4308769923 creator A5020718006 @default.
• W4308769923 creator A5022459181 @default.
• W4308769923 creator A5023213876 @default.
• W4308769923 creator A5025815003 @default.
• W4308769923 creator A5026642155 @default.
• W4308769923 creator A5028547482 @default.
• W4308769923 creator A5030365370 @default.
• W4308769923 creator A5030799737 @default.
• W4308769923 creator A5032474439 @default.
• W4308769923 creator A5036981821 @default.
• W4308769923 creator A5037814320 @default.
• W4308769923 creator A5038945821 @default.
• W4308769923 creator A5039342892 @default.
• W4308769923 creator A5042417820 @default.
• W4308769923 creator A5042617054 @default.
• W4308769923 creator A5043747371 @default.
• W4308769923 creator A5052210796 @default.
• W4308769923 creator A5052726683 @default.
• W4308769923 creator A5053288231 @default.
• W4308769923 creator A5058081440 @default.
• W4308769923 creator A5058094909 @default.
• W4308769923 creator A5061411814 @default.
• W4308769923 creator A5071482630 @default.
• W4308769923 creator A5076151386 @default.
• W4308769923 creator A5077554218 @default.
• W4308769923 creator A5079051965 @default.
• W4308769923 creator A5080267247 @default.
• W4308769923 creator A5083314956 @default.
• W4308769923 creator A5085355438 @default.
• W4308769923 creator A5085359664 @default.
• W4308769923 creator A5089158758 @default.
• W4308769923 creator A5090277186 @default.
• W4308769923 creator A5090753435 @default.
• W4308769923 creator A5091608218 @default.
• W4308769923 date "2022-11-10" @default.
• W4308769923 modified "2023-10-18" @default.
• W4308769923 title "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update" @default.
• W4308769923 cites W1996472975 @default.
• W4308769923 cites W1996543597 @default.
• W4308769923 cites W2009298607 @default.
• W4308769923 cites W2044940757 @default.
• W4308769923 cites W2054789510 @default.
• W4308769923 cites W2061796853 @default.
• W4308769923 cites W2089883381 @default.
• W4308769923 cites W2104669609 @default.
• W4308769923 cites W2110345763 @default.
• W4308769923 cites W2114909821 @default.
• W4308769923 cites W2118378094 @default.
• W4308769923 cites W2120393706 @default.
• W4308769923 cites W2129688566 @default.
• W4308769923 cites W2131882149 @default.
• W4308769923 cites W2133866209 @default.
• W4308769923 cites W2140082616 @default.
• W4308769923 cites W2140965629 @default.
• W4308769923 cites W2145881672 @default.
• W4308769923 cites W2151337536 @default.
• W4308769923 cites W2155109530 @default.
• W4308769923 cites W2160933699 @default.
• W4308769923 cites W2206432491 @default.
• W4308769923 cites W2471841098 @default.
• W4308769923 cites W2514249865 @default.
• W4308769923 cites W2549510815 @default.
• W4308769923 cites W2549844032 @default.
• W4308769923 cites W2619420016 @default.
• W4308769923 cites W2782562631 @default.
• W4308769923 cites W2891903398 @default.
• W4308769923 cites W2913977026 @default.
• W4308769923 cites W2920605646 @default.
• W4308769923 cites W2926455583 @default.
• W4308769923 cites W2971086071 @default.
• W4308769923 cites W3004695550 @default.
• W4308769923 cites W3005067674 @default.
• W4308769923 cites W3006080604 @default.
• W4308769923 cites W3007319208 @default.
• W4308769923 cites W3042161981 @default.
• W4308769923 cites W3068188279 @default.
• W4308769923 cites W3082892775 @default.
• W4308769923 cites W3099218816 @default.
• W4308769923 cites W3107208135 @default.
• W4308769923 cites W3126579487 @default.
• W4308769923 cites W3155177785 @default.
• W4308769923 cites W3164486644 @default.

• next